Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX launches subscription feature on its website

January 22, 2018


2cureX AB (“2cureX”) hereby announce that the company, as a service for its Investors, has made it possible to subscribe to news and press releases from the Company’s website ( Subscription can be made on both regulatory press releases and non-regulatory News. To subscribe to news from 2cureX, press this link:

Certified Adviser
Sedermera Fondkommission is designated Certified Advisor For 2cureX.

For more information about 2cureX, please contact:
Ole Thastrup, CEO
Telecommunicationsfon: + 45 22 11 53 99

About 2cureX
2cureX has developed IndiTreat ™ (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat™ is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).